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Abstract
Background: Initial success of electrical cardioversion (ECV) of atrial fibrillation (AF) has been
reported in several studies as 50%-90%, of which only 50% patients remain in sinus rhythm (SR) at
the end of one year. We conducted this study to see if outcomes of other trials are applicable in
managed care setting.
Methods: We conducted a retrospective study in 370 consecutive patients who underwent ECV
for AF. They were reviewed for initial outcome of ECV and recurrence of AF after a successful
ECV, with and without prophylactic antiarrhythmic drugs.
Results: Initial success of ECV for AF was 65.7%. At one year, 47% remained in SR. AF for ≤ 3
months (p = 0.006) and pretreatment with antiarrhythmic drugs (p = 0.032) resulted in improved
success. Predictors of recurrence were patients ≤ 65 years (p = 0.019), paroxysmal atrial fibrillation
(PAF) (p = 0.0094) and alcohol consumption (p = 0.0074).
Conclusion: Shorter duration of AF, prophylactic antiarrhythmic drugs and serial ECVs improve
outcome of ECV in AF. For younger patients with PAF and alcohol consumption, due to higher
recurrence of AF, rate control or ablative therapy may be the preferred strategy.
Introduction
Atrial Fibrillation (AF) is the most common dysrhythmia
encountered in clinical practice, accounting for approxi-
mately one third of hospitalizations for cardiac rhythm
disturbance. Electrical cardioversion (ECV) is used to
restore sinus rhythm (SR), both to alleviate associated
symptoms and to prevent congestive heart failure and
embolic complications.
The initial success of ECV has been reported as 50-90% in
prior studies [1,2]. It is reported that younger patients
with AF of less than 3 months duration are more likely to
respond to ECV than the elderly patients with AF for > 36
months [2]. However, up to half of the patients are
reported to have recurrence of AF within three to six
months with the highest number of recurrences in the first
8 weeks [1,3,4]. Similar rates of recurrence have been
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reported in patients with paroxysmal AF (PAF) or atrial
flutter [5]. Antiarrhythmic drugs have been used to
improve the immediate and long-term success of cardio-
version, but less favored due to unacceptable side effects
[6-8].
We conducted this study to see if the results of the trials
done at academic research centers with unrestricted avail-
ability of resources had similar outcome to that seen in a
managed care setting where the practice is done in a cost-
effective manner. This study was conducted to determine
the short-term and long-term success of ECV in a large
integrated managed care system. We also aimed to deter-
mine the predictors of initial success and recurrence of AF
after successful ECV, including antiarrhythmic drugs.
Methods
Study Patients
All 734 ECVs performed at a Health Maintenance Organ-
ization (HMO), Kaiser Permanente Hospital, Santa Clara,
California were identified from the hospital database by
the ICD-9-CD code for ECV. Patients with AF by electro-
cardiogram or diagnostic code were then selected. Of
these, medical records were available for retrospective
review on 400 patients. Thirty patients were excluded
because ECV was performed for ventricular tachycardia
and ventricular fibrillation, resulting in a study popula-
tion of 370 patients. An approval was obtained from the
Kaiser Permanente Northern California Institutional
Review Board (KPNC IRB). Anonymity of the patients was
strictly maintained in study databases.
Data Abstraction
Demographic information including age and gender,
duration of AF and date of ECV; history of recent smoking
and alcoholism were abstracted from the medical records.
Medical history was available from both written medical
records as well as from inpatient and outpatient electronic
databases. Comorbidities were tabulated including: con-
gestive heart failure, cardiomyopathy, valvular heart dis-
ease, chronic obstructive pulmonary disease,
hyperthyroidism, diabetes mellitus, coronary artery dis-
ease and hypertension. Echocardiographic data, when
available, were reviewed for left atrial (LA) dimension and
left ventricular (LV) systolic function.
In the absence of comorbidities, the patient was diag-
nosed as lone AF. Patients were classified as having: par-
oxysmal or persistent AF as per American College of
Cardiology/American Heart Association guidelines [9].
We pre-specified the following subgroups: Age ≤ 65 or >
65 years, male vs. female, duration of AF: 0-3 days, 4 days
to 3 months, > 3 months. New onset AF was defined as 0-
3 days.
Protocol
Written informed consent was obtained before the ECV
from each patient. Generally ECV was performed with
pacing pads placed anteriorly over the chest and posteri-
orly in the interscapular area, using single direction wave
shock with escalating energy levels (50-360 Joules) at the
discretion of the cardiologist. Patients who underwent
non-emergent ECV were anticoagulated with warfarin for
at least 4 weeks prior to the procedure and had therapeutic
INR at the time of ECV or underwent transesophageal
echocardiogram to rule out intracardiac thrombus. In case
of emergent ECV, intravenous heparin was administered.
At the time of ECV, if the patient was taking an
antiarrhythmic drug, it was recorded as ECV on
antiarrhythmic pretreatment. The ECV was defined as suc-
cessful if the patients were in SR immediately after the
procedure. Patients who underwent second ECV with or
without pretreatment with antiarrhythmic drugs were
recorded. All the charts were reviewed in the year post-car-
dioversion for recurrence of AF including outpatient visits,
emergency room visits or rehospitalization.
End Points
The primary end point of the study was immediate success
of ECV. The secondary end point was defined as the first
recurrence of AF after successful ECV.
Statistical Analysis
We conducted both univariate and multivariate analyses.
For the univariate analysis, we used Chi-square tests to
analyze the relationship between the variables as shown
in table 1 with the success/failure of ECV. For the multi-
variate analysis, logistic regression was used and adjusted
for all the variables. P-value of < 0.05 was considered sta-
tistically significant.
Results
Characteristics of patients are presented in table 1.
Twenty-seven patients (7.3%) had lone AF. The mean age
was 67 +/- 12 years. Of the 370 initial attempts at cardio-
version, 243/370 (65.7%) patients were successful. At the
end of one year, 175 patients remained in SR (72% of
those whose initial cardioversion was successful and 47%
overall) and 53% of the total were in AF. Of the 68
patients who relapsed into AF by one year, 58 patients
underwent repeat ECV. Thirty-six patients (36/127)
whose 1st cardioversion failed also underwent repeat
ECV, for a total of 94 patients undergoing 2nd ECV (Fig-
ure 1). Overall, 66/94 patients were on antiarrhythmic
drugs at the time of 2nd ECV. With the second attempt of
ECV, 72/94 (76.6%) patients were converted to SR.
Patients had a more favorable outcome with the 2nd ECV
as compared to initial ECV (76.6% vs 62.67%, p = 0.042).International Archives of Medicine 2009, 2:39 http://www.intarchmed.com/content/2/1/39
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Table 1: Characteristics of patients who underwent electrical cardioversion for atrial fibrillation
Total number of patients 370
Age of patients (mean ± SD years) 67 +/- 12
≤ 65 years 137
>65 years 233
Men/Women 239/131
Underlying coexisting diseases (number of patients)
Coronary artery disease 150
Congestive heart failure 116
Mitral stenosis 16
Mitral regurgitation 92
Paroxysmal atrial fibrillation 196
Hypertension 185
Cardiomyopathy 75
Diabetes mellitus 46
Chronic obstructive pulmonary disease 51
Alcoholism 105
Smoking 96
Lone atrial fibrillation 27
Duration of atrial fibrillation
0-3 days 91
4 days-3 months 105
>3 months 174
Left atrial size (157 patients)
≤ 4.2 cm 72
>4.2 cm 85
Left Ventricular Ejection Fraction
Normal 129
Reduced 40International Archives of Medicine 2009, 2:39 http://www.intarchmed.com/content/2/1/39
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Effect of Antiarrhythmics
Antiarrhythmic drugs included procainamide, amiodar-
one, quinidine, ibutilide, propafenone, sotalol or flecain-
ide according the preference of the treating physician
(table 2). Eighty-six patients (86/370) were receiving
antiarrhythmic drugs at the time of 1st ECV. Of these,
more patients (n = 65) on antiarrhythmic drugs success-
fully converted to normal SR after ECV compared to those
not receiving (n = 178) antiarrhythmic drugs (75.6% vs.
62.7%, p = 0.027). Using logistic regression to adjust for
all the variables in table 1, antiarrhythmic use remained
independently associated with successful cardioversion (p
= 0.032, Table 3). Of the 94 patients undergoing 2nd ECV,
66 were receiving antiarrhythmic drugs (figure 2). There
was no significant difference in the success of 2nd ECV
between those receiving and not receiving antiarrhythmic
drugs (75.7% vs 78.6%, p = 0.768). Antiarrhythmic drugs
did not decrease the incidence of recurrence of AF after a
successful ECV (45/65, 69% vs. 130/178, 73%, p = NS).
Two patients on antiarrhythmics had spontaneous con-
version to SR after failed initial ECV.
Predictors of Short-term and Long-term Success of ECV in 
AF
Age and Sex
The success rate was similar in younger and older patients
after the 1st ECV (≤ 65 years: 65.7% vs >65 years: 65.7%).
However, a greater number of younger patients relapsed
in to AF during the course of one year (≤ 65 years: 35% vs
>65 years: 22%, p = 0.009 by univariate analysis).
Younger patients were twice as likely to have recurrence of
AF even after adjusting to gender, duration of AF and
comorbid conditions (p = 0.019, OR = 2.24, 95% confi-
dence intervals, table 4).
By univariate analysis, females had greater success with
initial ECV than males (Females: 72.52% vs Males: 62%,
p = 0.04). But, when adjusted for comorbid conditions,
sex did not did not affect the success of ECV or relapse of
AF.
Co-morbid Conditions
None of the coexisting medical problems significantly
influenced the immediate outcome of initial ECV or
repeat ECV for recurrent AF.
Results of serial electrical cardioversion in atrial fibrillation  and follow-up over one year Figure 1
Results of serial electrical cardioversion in atrial 
fibrillation and follow-up over one year. (ECV-Electrical 
cardioversion, AF-atrial fibrillation).
    
           
        
           
  
           
        
1st ECV 
n=370 
Successful ECV 
n=243 (66 %) 
Unsuccessful ECV 
n=127 (34%) 
Sinus rhythm 
n=175 
Relapse to AF 
n=68 
Successful 
n=72 (76.6%)
Unsuccessful 
n=22 (23.4%)
2nd ECV (58+36=94) 
At one year 
Table 2: Outcome of electrical cardioversion in atrial fibrillation on prophylactic antiarrhythmic treatment before the 1st and 2nd 
electrical cardioversion
Antiarrhythmic drug Patients with successful 1st ECV (%) Patients with successful 2nd ECV (%)
Procainamide 22 (73) 5 (71)
Amiodarone 15 (75) 17 (59)
Quinidine 9 (75) 2 (100)
Ibutilide 6 (75) 4 (100)
Propafenone 6 (86) 3 (100)
Sotalol 6 (86) 17 (94)
Flecainide 1 (50) 2 (67)
No drug 178 (63) 22 (79)International Archives of Medicine 2009, 2:39 http://www.intarchmed.com/content/2/1/39
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Patients with PAF (p = 0.009) and history of alcohol con-
sumption (p = 0.007) had a significantly higher likeli-
hood of recurrence of AF within one year after successful
ECV (Table 4).
Duration of AF
Duration of AF was inversely related to initial success rate
(0-3 days: 76.9%, 4 days-3 months: 65.7%, > 3 months:
59.8%), (Figure 3). The difference between 0-3 days and >
3 months was significant (p = 0.003) while the difference
between 4 days-3 months and > 3 months was not (p =
0.11). Recurrence of AF in these three groups after success-
ful ECV was not affected by duration of AF.
Echocardiographic Parameters
Echocardiography reports were available on 169 patients.
LA dimension was reported in 157 patients that ranged
from 3.2 cm to 7.0 cm. In our observation, LA size did not
influence the short or long term success of ECV (≤ 4.2 cm:
71.8% vs. >4.2 cm: 61.6%, p = 0.10). No significant differ-
ence was noted when different cut-off values (LA size of
4.6 cm and 5.0 cm) were analyzed. LV systolic function
was reported as normal in 129 patients and reduced in 40
patients; LV dysfunction did not correlate with success of
initial ECV.
In the cohort of patients with known LA size (157
patients), after adding the LA size to the other parameters
in logistic regression analysis, the positive predictors of
success including shorter duration of AF and prophylactic
antiarrhythmic drugs seen in the entire group was not
observed. However, patients with a history of alcohol con-
sumption had lower success of ECV if LA size was > 4.2 cm
(p = 0.04). Younger patients had more recurrences in this
group as well (p = 0.007).
Discussion
This is the largest study involving consecutive patients
undergoing ECV within an integrated medical delivery
system. The extensive database available within this HMO
provided unique clinical information since most patients
used this facility exclusively for their health care.
In this population, overall success of ECV in restoring AF
to SR at our facility was 67%, which falls in the wide range
reported in the literature [1,2]. Shorter duration of AF of
0-3 days was a significant determinant of successful ECV,
which is in accordance to prior trials [2,10]. Interestingly,
the long-term recurrence of AF after ECV was not affected
by the duration of AF in our study. In contrast, Frick et al
followed the patients for short-term of one month after
ECV and reported that a duration of AF < 6 months pre-
dicted success [11]. In another study, duration of AF < 1
year predicted success [12]. Based on the variable results,
it is reasonable to attempt ECV in patients with AF even in
those with unknown duration of AF. Besides duration of
AF, pretreatment with antiarrhythmic drugs predicted suc-
cessful ECV.The benefit of antiarrhythmic drugs prior to
cardioversion for initial restoration of sinus rhythm was
similar to several prospective trials [7,13-15], supporting
their use when possible. This observed benefit needs to be
weighed against the potential adverse side effects of these
agents and the potential delay in offering cardioversion.
But unlike other studies [8,16], antiarrhythmic drugs did
Table 3: Co-morbidities affecting success of initial electrical cardioversion (logistic regression)
Parameter p-value Odds Ratio Estimates
(95%) Confidence Intervals
Age: ≤ 65 and > 65 years 0.532 0.519 1.404
Sex: Male vs. Female 0.086 0.939 2.578
Duration: ≤ 3 m vs. > 3 months 0.006 0.332 0.837
Duration: 0-3 days vs. > 3 months 0.003 1.361 4.693
Duration: 4 days-3 m vs. > 3 months 0.113 0.902 2.655
On antiarrhythmic medications 0.032 1.056 3.420
Lone atrial fibrillation 0.736 0.325 2.215
Congestive heart failure 0.406 0.437 1.398
Cardiomyopathy 0.968 0.531 1.934
Mitral stenosis 0.517 0.393 6.390
Mitral regurgitation 0.684 0.612 2.111
Pulmonary Disease 0.533 0.372 1.669
Diabetes mellitus 0.070 0.942 4.525
Coronary artery disease 0.414 0.744 2.049
Hypertension 0.867 0.592 1.556
Paroxysmal atrial fibrillation 0.498 0.726 1.932
Alcoholism 0.173 0.410 1.175
Smoking 0.682 0.617 0.092International Archives of Medicine 2009, 2:39 http://www.intarchmed.com/content/2/1/39
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Results of serial electrical cardioversion in atrial fibrillation in patients after prophylactic antiarrhythmic drugs and follow-up  over one year Figure 2
Results of serial electrical cardioversion in atrial fibrillation in patients after prophylactic antiarrhythmic drugs 
and follow-up over one year. (ECV-Electrical cardioversion, AF- atrial fibrillation).
Total 2nd ECV (n=94)  
On antiarrhythmics (n=66) 
Successful ECV 
n=65 (75.6 %) 
Unsuccessful ECV 
n=21 (24%) 
Sinus rhythm 
n=45 
Relapse to AF 
n=20 
Successful (n=50)  Unsuccessful (n=22) 
16                                     6 
On antiarrhythmics before 2
nd ECV  
Started on antiarrhythmics 
after unsuccessful 1st ECV 
(n=27)
Started on antiarrhythmics 
after relapse of successful 
1st ECV- (n=17)
At one year 
1st ECV on antiarrhythmic drugs 
n=86 
Table 4: Co-morbidities affecting recurrence of atrial fibrillation after a successful electrical cardioversion (logistic regression)
Parameter p-value Odds Ratio Estimates
(95%) Confidence Intervals
Age: ≤ 65 vs. > 65 years 0.019 1.136 4.424
Sex: Male vs. Female 0.815 0.536 2.205
Duration: 0-3 days vs. > 3 months 0.607 0.380 1.759
Duration: 4 days-3 m vs. > 3 months 0.692 0.539 2.535
On antiarrhythmic medication 0.948 0.475 2.006
Lone atrial fibrillation 0.405 0.089 2.661
Congestive heart failure 0.884 0.413 2.142
Cardiomyopathy 0.885 0.373 2.343
Mitral stenosis 0.422 0.429 7.533
Mitral regurgitation 0.293 0.277 1.473
Pulmonary Disease 0.540 0.209 2.270
Diabetes mellitus 0.061 0.124 1.048
Coronary artery disease 0.760 0.570 2.158
Hypertension 0.904 0.500 1.848
Paroxysmal atrial fibrillation 0.009 1.257 5.149
Alcoholism 0.007 1.306 5.627
Smoking 0.099 0.183 1.157International Archives of Medicine 2009, 2:39 http://www.intarchmed.com/content/2/1/39
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not reduce relapses significantly in our study which could
be limited by small sample size and unavailable informa-
tion about the duration of therapy and withdrawals.
In the follow-up over one year, 72% of the patients who
were successfully cardioverted to normal SR remained in
SR. Overall, 53% of the study patients were in AF at one
uear follow-up, as compared to 46% patients noted in
AFFIRM trial [17]. Several parameters were found to affect
the recurrence of AF after a successful ECV, including age
younger than or equal to 65 years, history of PAF and alco-
hol consumption. The higher recurrence of AF in younger
patients after a successful ECV is contrary to other reports
[1,2], possibly due to the younger patients in our study
having higher rates of alcohol consumption and PAF. This
is an important observation for younger patients who may
have limitations in activities and are reluctant to take
drugs as they may be better served with ablative therapies.
In the Framingham study, the authors observed little asso-
ciation between moderate alcohol consumption and the
risk of AF, but a significantly increased risk of AF with a
consumption of > 36 g/day or about 3 drinks/day [18]. It
also brings up an important question whether some
patients were actually not appropriate candidates for ECV,
such as those with significant triggering factors like alco-
hol leading to recurrence. Rate control strategy may be
preferable in such patients.
A high rate of successful repeat ECV in patients with failed
initial ECV or relapse after a successful initial ECV was
noted. Van Gelder et al have reported that serial ECV may
be beneficial in younger patients with fair exercise toler-
ance and with shorter than 36 months duration of AF [2].
In our study, patient's age did not affect the success/failure
rate of initial ECV, which is accordance with the results of
prior studies [10,19]. LA dimension and LV systolic func-
tion also did not predict successful ECV in AF. Although
this finding may have been affected by the availability of
this echocardiographic data in only a subset or our
patients, prior studies have not consistently shown an
effect of LA dimension and LV function on success of ECV
[20,21]. In clinical practice, however, ECV is commonly
offered for AF to patients with large atria and reduced LV
function. Larger LA does not preclude a favorable out-
come of ECV in AF and results in reversal of atrial size [22]
Rate vs rhythm control strategies have been studied by
large prospective trials, and have concluded that the two
approaches are associated with similar morbidity, cardio-
vascular events, stroke and quality of life [23,24]. All of
the patients in the RACE trial had a minimum of one prior
cardioversion. The majority of patients in the AFFIRM trial
had also been previously cardioverted. In a subset of
patients with pre-existing heart failure (23% of the popu-
lation), rhythm control actually seemed to be favorable.
Rhythm control strategy may be the preferred treatment of
choice for patients with disabling symptoms due to AF.
Loss of atrial contribution to ventricular filling can lead to
hemodynamic deterioration in patients with preload
dependent lesions such as aortic stenosis and diastolic
heart failure. In elderly patients with persistent arrhyth-
mia, cognitive function may be impaired as compared
with age-matched controls in sinus rhythm [25], probably
due to chronic hypoperfusion or cerebral microembo-
lism.
Persistent AF over long duration is known to cause electro-
physiological, anatomic, and pathological changes, with
decreased atrial refractoriness [26,27]. This results in
higher incidence of failure of ECV in patients with longer
duration of AF (> 3 months) as seen in our study as well
as in prior trials [2,10], which reinforces the need to
attempt cardioversion, if planned, as early as possible.
Even intermittent AF can lead to atrial fibrosis increasing
the risk of persistent AF [28]. Radiofrequency ablation
and pulmonary vein (PV) isolation are evolving tech-
niques in patients with refractory AF. PV isolation is par-
ticularly beneficial in PAF, which have shown to reduce
the recurrences of AF and improve the quality of life even
after recurrences [29-31]. Khargi et al showed better suc-
cess rate after Cox-Maze III procedure in younger patients
with PAF [32].
Limitations
There are several limitations to our study related to its ret-
rospective, nonrandomized study design. Although our
registry provided extensive, reliable data, there were miss-
ing data points. The history of alcohol intake by the sub-
jects cannot be clarified to know the amount and
frequency of alcohol consumption. Neither the duration
or doses of antiarrhythmic drugs nor any proarrhythmic
Effect of duration on the success of electrical cardioversion  in atrial fibrillation Figure 3
Effect of duration on the success of electrical cardio-
version in atrial fibrillation.
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events were recorded. Another limitation is that recur-
rence of AF is based on intermittent and inconsistent
monitoring. Studies with continuous monitoring with an
implantable monitoring device have demonstrated higher
rates of recurrence [33].
Conclusions
In the managed care setting, the success of ECV is compa-
rable to the results of other centers, with two thirds of
patients showing immediate success of ESV and about
50% patients remaining in SR at the end of one year.
Patient's age may not predict the initial success of electri-
cal cardioversion. A longer duration of AF (>3 months)
can be associated with lower success rate of ECV and serial
ECV may improve the outcome. Higher relapses of AF
after successful ECV in younger patients with PAF and his-
tory of alcohol consumption suggests that rate control or
ablative therapy may be the preferred strategy for these
patients. Antiarrhythmic drugs can improve the outcome
of ECV, but their use requires careful weighing of poten-
tial risks and benefits.
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